CLAIMS

1. A spontaneously dispersible pharmaceutical composition for oral administration comprising
1) N-benzoyl-staurosporine,
2) a hydrophilic component, and
2) a surfactant.

2. A composition as claimed in claim 1 further comprising a lipophilic component.

3. A composition as claimed in claim 1 or claim 2 wherein the hydrophilic component comprises ethanol, 1,2-propylene glycol or a polyethylene glycol.

4. A composition as claimed in any preceding claim wherein the surfactant is selected from the group consisting of polyoxyethylenes, polyglycerols and related polyols, and polyalkylene oxide copolymers.

5. A composition as claimed in any preceding claim wherein the surfactant is selected from the group consisting of a polyoxyethylene castor oil, a polyoxyethylene alkyl ether, and a polysorbate.

6. A composition as claimed in any preceding claim wherein the surfactant has an HLB value of greater than 10 and the composition further comprises a co-surfactant having an HLB value of less than 10.

7. A composition as claimed in claim 6 wherein the surfactant is selected from the group consisting of a polyoxyethylene castor oil, a polyoxyethylene alkyl ether, and a polysorbate, and the co-surfactant comprises a transesterified ethoxylated vegetable oil.

8. A composition as claimed in claim 2 wherein the surfactant has an HLB value of greater than 10 and the lipophilic component comprises a fatty acid glyceride.

9. A spontaneously dispersible pharmaceutical composition for oral administration comprising

(a) up to 20% by weight of N-benzoyl-staurosporine,

(b) 5 to 50% by weight of a hydrophilic component,

(c) 5 to 80% of a surfactant or surfactant mixture,

(d) 5 to 85% of a lipophilic component, and

(e) 0.05 to 5 % of an additive.

10. A method of treatment for treating subjects in need of N-benzoyl-staurosporine therapy comprising administering a dispersible pharmaceutical composition according to any preceeding claim to a subject in need of such treatment.

11. A pharmaceutical composition for oral administration comprising N-benzoylstaurosporine and having

(a) a variability of bioavailability levels of N-benzoylstaurosporine of from 5 to 17%;

(b) an AUC (0-48h)/dose value (in (h•nmol/L)/(mg/kg)) of from 380 to 2000, or

(c) a C_{max}/dose value (in (nmol/L)/(mg/kg)) of from 60 to 310,

upon administration of a dose (in mg/kg) of N-benzoylstaurosporine to fasted beagle dogs.

12. A method of increasing bioavailability levels or reducing variability of bioavailability levels of N-benzoylstaurosporine by mixing N-benzoylstaurosporine with a carrier comprising a hydrophilic component, and a surfactant.

13. A method of increasing bioavailability levels or reducing variability of bioavailability levels of N-benzoylstaurosporine, said method comprising orally administering a composition according to any preceding claim to fasted beagle dogs.